Flucytosine and fluconazole + Fluconazole
Phase 2Terminated 0 watching 0 views this week⚡ Active
47
Development Stage
✓
Pre-clinical✓
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Cryptococcal Infection Disseminated
Conditions
Cryptococcal Infection Disseminated
Trial Timeline
Sep 1, 2013 → Jul 1, 2014
NCT ID
NCT01562132About Flucytosine and fluconazole + Fluconazole
Flucytosine and fluconazole + Fluconazole is a phase 2 stage product being developed by Bausch Health for Cryptococcal Infection Disseminated. The current trial status is terminated. This product is registered under clinical trial identifier NCT01562132. Target conditions include Cryptococcal Infection Disseminated.
Hype Score Breakdown
Clinical
17
Activity
12
Company
5
Novelty
5
Community
5
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT01562132 | Phase 2 | Terminated |
Competing Products
18 competing products in Cryptococcal Infection Disseminated
| Product | Company | Stage | Hype Score |
|---|---|---|---|
| Efungumab (Mycograb) + placebo + Amphotericin B + 5 flucytosine | Novartis | Phase 2 | 52 |
| Mycograb + placebo | Novartis | Phase 2 | 52 |
| Single dose liposomal Amphotericin and Fluconazole + Fluconazole | Gilead Sciences | Phase 2/3 | 64 |
| Fluconazole | Pfizer | Pre-clinical | 22 |
| Fluconazole | Pfizer | Pre-clinical | 22 |
| Fluconazole + Amphotericin B | Pfizer | Pre-clinical | 22 |
| Flucytosine + Fluconazole | Pfizer | Pre-clinical | 22 |
| Fluconazole + Amphotericin B | Pfizer | Pre-clinical | 22 |
| Flucytosine + Fluconazole + Amphotericin B | Pfizer | Pre-clinical | 22 |
| Fluconazole | Pfizer | Pre-clinical | 22 |
| Fluconazole | Pfizer | Pre-clinical | 22 |
| Fluconazole + Amphotericin B | Pfizer | Phase 3 | 76 |
| Flucytosine + Fluconazole + Amphotericin B | Pfizer | Pre-clinical | 22 |
| Fluconazole | Pfizer | Pre-clinical | 22 |
| Lobradimil + Amphotericin B | Alkermes | Phase 1 | 30 |
| MAT2203 + Amphotericin B | Matinas Biopharma | Phase 1/2 | 33 |
| Encochleated Amphotericin B | Matinas Biopharma | Phase 1/2 | 33 |
| MAT2203 + Amphotericin B | Matinas Biopharma | Phase 3 | 69 |